| Bioactivity | Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2]. |
| Invitro | Donanemab 是一种针对 N 末端焦谷氨酸 Aβ 表位的人源化 IgG1 抗体，该表位仅存在于已建立的斑块中。Donanemab 对该表位具有特异性，并且未显示与其他 Aβ 种类、神经递质或其受体的脱靶结合[2]。 |
| Name | Donanemab |
| CAS | 1931944-80-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. [2]. Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704. |